Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighed on expectations and investors reacted.
Alnylam cut 2026 guidance ($5.275-5.725B) as Amvuttra second-line demand normalized. Stock fell 29%. Ionis trial failure in ATTR-CM gene-silencing raises efficacy concerns; Alnylam's Nucresiran Phase 3 faces program risk, signaling broader biotech R&D portfolio pressure.
Alnylam Pharmaceuticals Inc.
(NASDAQ:ALNY) stock plunged on Thursday after the company lowered its fiscal 2026 guidance.
The company reported second-quarter adjusted earnings of $1.84 per share, beating the consensus of $1.55.
Sales jumped 67% year over year to $1.291 billion, missing the consensus of $1.323 billion.
Achieved global net product revenues for Amvuttra and Onpattro for the second quarter of $1,012 million and $18 million, respectively.
Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock
Alnylam shares tank 29% as Amvuttra disappoints with ATTR outlook cut for 2026
Alnylam's stock is down 30% despite a booming biotech market. Here's why.
Alnylam plunges as earnings deliver ‘one-two punch’
Alnylam's slump deepens; Q2 earnings roundup; and more
Biogen flips '26 guidance from expected decline to sales increase
